To this end, even during its perturbing action on the renin-angiotensin-Aldo system [5,6,42,49], findings from this study also highlight an important alternative aspect that needs to be taken into consideration, inasmuch as the beneficial effects of ESAX in different pathologic disorders, such as primary hyperaldosteronism, chronic kidney disease, refractory hypertension, and heart failure, have been currently evaluated [1,3,4,5,6,9,39,49,50,51]. The gene discussed is REN; the disease is heart failure.